DNLI insider files Form 144 for 2,937 vested shares on NASDAQ

Rhea-AI Filing Summary

Denali Therapeutics Inc. has submitted a Form 144 notifying a proposed sale of 2,937 common shares with an aggregate market value of $39,875.82. The shares were acquired on 08/11/2025 due to a restricted stock lapse as equity compensation, and the filing lists an approximate sale date of 08/12/2025. The transaction is to be executed through Morgan Stanley Smith Barney LLC on NASDAQ.

The shares represent roughly 0.002% of the issuer's reported 146,419,263 shares outstanding. The filer reports Nothing to Report for securities sold in the past three months. This notice is a routine disclosure of intent to sell vested equity and contains no additional material items beyond the transaction details provided.

Positive

• Clear compliance: Filing provides required Rule 144 details including acquisition date, sale date, broker, and amount.
• Small size: 2,937 shares equal roughly 0.002% of 146,419,263 shares outstanding, indicating negligible market impact.
• Equity compensation: Shares were acquired via a restricted stock lapse, a routine corporate compensation event.

Negative

• None.

Insights

Securities Analyst

TL;DR Small post-vesting insider sale; size is immaterial to market given the full share count.

The Form 144 shows a proposed sale of 2,937 shares valued at $39,875.82, acquired via a restricted stock lapse on 08/11/2025 and to be sold the next day through Morgan Stanley on NASDAQ. Relative to the reported 146,419,263 shares outstanding, the position equals roughly 0.002%, which is negligible from a supply/demand perspective. The filer reports no other sales in the prior three months, indicating this is a routine liquidity event tied to equity compensation rather than a broader disposition.

Corporate Governance Expert

TL;DR Filing is standard Rule 144 compliance after vesting; disclosure meets required transparency standards.

The notice documents an insider's intent to sell vested restricted stock acquired as equity compensation. The prompt disclosure of acquisition date (08/11/2025), acquisition nature (restricted stock lapse), and broker details (Morgan Stanley Smith Barney LLC) aligns with Rule 144 reporting expectations. Given the small size of the proposed sale and the lack of recent sales activity, the transaction does not signal governance or stewardship concerns based on the information presented.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 38th Fl. New York NY 10004	2937	39875.82	146419263	08/12/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	08/11/2025	Restricted Stock Lapse - See Remarks	Denali Therapeutics Inc.			2937	08/11/2025	Equity Compensation

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does Denali Therapeutics (DNLI) Form 144 report?

The Form 144 notifies a proposed sale of 2,937 common shares acquired via restricted stock lapse, with an aggregate value of $39,875.82.

When were the DNLI shares acquired and when is the sale planned?

The shares were acquired on 08/11/2025 upon restricted stock lapse and the approximate sale date listed is 08/12/2025.

Through which broker will the DNLI shares be sold?

The proposed sale is to be executed through Morgan Stanley Smith Barney LLC on NASDAQ.

How material is the proposed DNLI sale relative to outstanding shares?

The 2,937 shares represent about 0.002% of the reported 146,419,263 shares outstanding, which is immaterial.

Does the filing show any DNLI securities sold by this person in the past three months?

The filer reports Nothing to Report for securities sold in the past three months.